platinum has been researched along with osimertinib in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 9 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, M-J; Akamatsu, H; Garassino, MC; Ghiorghiu, S; He, Y; Kim, HR; Lee, CK; Mann, H; Marotti, M; Mok, TS; Papadimitrakopoulou, VA; Ramalingam, SS; Sebastian, M; Shepherd, FA; Templeton, A; Theelen, WS; Wu, Y-L | 1 |
| Pinion, S | 1 |
| Bijwaard, K; Blumenthal, GM; Donoghue, M; Fan, I; Fiero, MH; Goldberg, KB; Keegan, P; Larkins, E; Lee, EY; Mathieu, L; McKee, A; Odogwu, L; Pazdur, R; Philip, R; Rodriguez, L | 1 |
| Andersohn, F; Bodnar, C; Hoyle, C; Mann, H; Mitsudomi, T; Mok, TSK; Yang, JC | 1 |
| Akamatsu, H; Hida, T; Hodge, RA; Imamura, F; Katakami, N; Kato, T; Kim, YH; Okamoto, I; Shinkai, M; Uchida, H | 1 |
| Akamatsu, H; Chang, GC; Delmonte, A; Huang, X; Jenkins, S; John, T; Lee, JS; Su, WC; Wu, YL | 1 |
| Ishiki, H; Kiuchi, D; Kubo, E; Satomi, E; Shimizu, M; Tanaka, T; Yokota, S | 1 |
| Ahn, MJ; Akamatsu, H; Delmonte, A; Han, JY; He, Y; John, T; Kim, SW; Laskin, J; Laus, G; Mann, H; Miranda, M; Mok, TS; Papadimitrakopoulou, VA; Ramalingam, SS; Rukazenkov, Y; Sebastian, M; Shepherd, FA; Su, WC; Theelen, WSME; Wu, YL | 1 |
| Asahina, H; Isobe, T; Kagamu, H; Kikuchi, T; Kobayashi, K; Maemondo, M; Morita, S; Oizumi, S; Okamoto, I; Seike, M; Sugio, K; Takahashi, K; Tanaka, K | 1 |
| Chen, TT; Cunanan, K; Das, M; Gardner, RM; Neal, JW; Padda, SK; Piotrowska, Z; Piper-Vallillo, AJ; Ramchandran, K; Sequist, LV; Wakelee, HA; White, MN | 1 |
| Azuma, K; Fujimoto, D; Hasegawa, K; Hayakawa, D; Hayashi, H; Iwama, E; Kato, T; Nakagawa, K; Nakamura, A; Nosaki, K; Oki, M; Shimokawa, M; Tachihara, M; Takahashi, T; Takeda, M; Tanaka, H; Watanabe, Y; Yamaguchi, K; Yamamoto, N; Yamamoto, S | 1 |
| Carbone, DP; Furuya, N; He, K | 1 |
| Hayashi, H; Kasahara-Kiritani, M; Nishio, M; Takahashi, M; Tsuchiya, H | 1 |
| Goto, Y; Gyotoku, H; Harada, D; Kogure, Y; Murakami, S; Ninomiya, K; Nomura, S; Okamoto, H; Okishio, K; Okuma, Y | 1 |
| Patel, JD; Patel, S | 1 |
1 review(s) available for platinum and osimertinib
| Article | Year |
|---|---|
Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study).
Topics: Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors | 2023 |
9 trial(s) available for platinum and osimertinib
| Article | Year |
|---|---|
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Piperazines; Platinum; Young Adult | 2017 |
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Platinum; Protein Kinase Inhibitors; Remission Induction; Risk Assessment; United States; United States Food and Drug Administration; Young Adult | 2018 |
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Meta-Analysis as Topic; Middle Aged; Mutation; Piperazines; Platinum; Propensity Score; Protein Kinase Inhibitors | 2018 |
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Anemia; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Piperazines; Platinum; Protein Kinase Inhibitors; Young Adult | 2018 |
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Pemetrexed; Platinum; Progression-Free Survival; Prospective Studies; Retrospective Studies | 2018 |
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Topics: Acrylamides; Adult; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors; Survival Analysis | 2020 |
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Progression-Free Survival; Safety; Treatment Outcome | 2021 |
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemothera
Topics: Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors | 2023 |
Patients' voice and passion lead to successful clinical trial, KISEKI study; Comments on "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progresse
Topics: Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors | 2023 |
5 other study(ies) available for platinum and osimertinib
| Article | Year |
|---|---|
Osimertinib improves progression-free survival in NSCLC.
Topics: Acrylamides; Aniline Compounds; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Progression-Free Survival; Protein Kinase Inhibitors | 2017 |
Is Gefitinib Combined With Platinum-Doublet Chemotherapy a Counterpart to Osimertinib Monotherapy in Advanced
Topics: Acrylamides; Aniline Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2020 |
Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Immunotherapy; Lung Neoplasms; Mutation; Platinum; Retrospective Studies | 2022 |
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Platinum; Protein Kinase Inhibitors; Treatment Outcome | 2023 |
Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors | 2023 |